We are building a scalable platform with state-of-the-art centers that champion clinical trials and showcase the clinic of the future—which we believe is the best way to ensure long-term acceptance of these new therapies

Sunstone is a leader in the delivery of psychedelic-assisted therapy in the medical setting, offering a business model that can make care more widely available. We are focusing on the development and execution of clinical trials today and moving toward clinical delivery if and when therapies are approved.

Sunstone designs and delivers clinical trials across multiple medicines and treatment indications to inform patient experience and FDA regulation. We are setting the bar high with an absolute commitment to providing a safe, trustworthy space for psychedelic-assisted therapy

Sunstone has the most open clinical trials and has treated more patients with psychedelics (excluding ketamine) than any other clinic or center in the country. Learnings from our clinical trials help us develop new standards for delivery in this emerging field and deliver immersive training simulations and education, focusing on all aspects of delivery.

The administration of psychedelic therapies is complex, necessitating extensive expertise in logistics, infrastructure, training, and clinical intervention. Sunstone’s experience in oncology care affords us a distinct and effective approach to these challenges. We maintain a detailed and efficient approach to planning, delivering, and measuring outcomes.